In short
The FDA removed “black box” warnings from hormone replacement therapies (HRT) for menopause symptoms, prompting discussion of whether HRT is safer than previously believed and how timing affects risks.
Guest
Dr. Fannie Allahi, Associate Professor of Neurology and Neuroscience at the Icahn School of Medicine at Mount Sinai (New York City). She previously discussed HRT potentially reducing dementia risk.
Key claims
The prior warnings were based on a flawed Women’s Health Initiative design and the “timing of treatment” (tested in women starting in their mid-60s) was too late; physiology changes after menopause. HRT is “no longer considered risky” in the right clinical setting, but duration of use remains uncertain.
Notable examples
Analogy to testing Alzheimer’s treatment only after full dementia; estrogen-only therapy may increase uterine cancer risk, requiring close monitoring if the uterus remains. Route matters (oral estrogen can raise coagulation risk). Breast cancer risk increase “independent of other risk factors” is no longer considered true.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOIntroduction to Women's Health Segment
0:30 to 0:49
Transition into the segment focused on women's health issues.
“Small businesses are the pulse of every community.”
Introduction to Women's Health Segment
0:53 to 2:08
Transition into the segment focused on women's health issues.
“The Chase mobile app is available for select mobile devices.”
Introduction to Women's Health Segment
2:12 to 2:26
Transition into the segment focused on women's health issues.
“Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut.”
FDA Changes on Hormone Replacement Therapy
2:26 to 3:53
Discussion on FDA's removal of strict warnings on HRT.
“We want to get to our weekly segment, Business Week Women's Health Segment, where we focus on key issues in developing technologies impacting the present and future of women's health around the world.”
Historical Context of HRT Warnings
3:53 to 5:48
Exploration of why previous warnings on HRT were in place.
“And during this time, many women did not get the chance to go on hormone replacement therapy due to the fear of the side effects that were not indicated.”
Timing and Administration of HRT
5:48 to 9:11
Insights on when women should consider HRT and its implications.
“It's like having a treatment for Alzheimer's disease for the early, you know, most, maybe even preclinical stage of disease, but waiting until full-blown dementia to test it.”
Debunking HRT Risks
9:11 to 10:07
Discussion on cancer risks associated with HRT and the importance of monitoring.
“I know we're not supposed to do this, but will you be my doctor?”
Precision Medicine and HRT
10:07 to 11:05
Exploring the future of hormone therapy in precision medicine.
“so appreciate it already looking forward to next time Dr.”
Transcript
Automatic transcript. May contain errors.0:00What if data didn't sit still? What if intelligence moved with us? Not buried in reports, but activated in real time, where lives are being shaped, where decisions are being made. It all starts with a question. Where is the potential? Cotality turns data into clarity, intelligence into insight, insight into action. Because when intelligence moves, we all move forward. Cotality. Intelligence beyond bounds. Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. Chase for Business helps business owners like you with personalized guidance and convenient digital tools all in one place.
0:42With that guidance and your determination, you can take your business farther and help build a brighter future for your community. Learn more at chase.com slash business. Chase for Business. Make more of what's yours. The Chase mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank, NA. Member FDIC. Copyright 2026. JPMorgan Chase and Company. So there's a lot of noise about AI, but time's too tight for more promises. So let's talk about results. At IBM, we work with our employees to integrate technology right into the systems they need. Now, a global workforce of 300 ,000 can use AI to fill their HR questions, resolving 94 % of common questions.
1:26Not noise. Proof of how we can help companies get smarter by putting AI where it actually pays off, deep in the work that moves the business. Let's create smarter business. IBM. When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges. At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience.
2:08Learn more at thehartford.com slash risk mitigation. Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut. Bloomberg Audio Studios. Podcasts, radio, news. You're listening to Bloomberg Business Week with Carol Masser and Tim Stenevek on Bloomberg Radio. We want to get to our weekly segment, Business Week Women's Health Segment, where we focus on key issues in developing technologies impacting the present and future of women's health around the world. And a lot of times it's women's health, but also even more generally a look at major health issues.
2:49And this week, though, definitely pertains to women. We're talking about hormone replacement therapies used to treat menopause symptoms, no longer needing to carry strict warnings about some potential side effects, including cancer and heart disease. That came from the U.S. Food and Drug Administration earlier in the week. Actually, on Monday it came. So we wanted to get to a voice that we've talked to before, and it's great to have her back with us. Dr. Fannie Law, she is Associate Professor of Neurology and Neuroscience at the Icahn School of Medicine at Mount Sinai. She joins us from New York City.
3:19As Carol mentioned, this week the FDA said it would remove the black box warnings from HRT products. The last time you were on the show with us, you said HRT may actually help diminish women's risk of dementia. What are your views on just the warning or the changing warnings coming from the federal government on this? Net-net, a good thing? So I want to qualify that statement by I hope that it will diminish the risk of dementia. I am delighted by the fact that this warning that I and many others think was never warranted was finally lifted. It's sad that we lost two decades. And during this time, many women did not get the chance to go on hormone replacement therapy due to the fear of the side effects that were not indicated.
4:06But I think now we need to make up for the lost time and advance the science to the point where we are more precise with our predictions. Why were those statements there in the first place? If we go back in history, you said we lost it's unfortunate that we lost 20 years of treatment here. Why do those those come around in health care in the U.S. in the first place? It was unfortunately a flawed design. Hormone replacement therapy was started for women who had gone through menopause in their 50s. And it wasn't until mid 60s that hormone replacement therapy was started. By then, it's too late. The physiology has drastically changed.
4:52A decade has gone by. And the impact of hormones may no longer have the impact on the health span that we need them to have. And then you just deal with the side effects. Wait, so I'm confused. You're saying not as dangerous. So and what a shame that women weren't allowed to use them earlier because there were these concerns and warnings on it. Right. So what I'm saying is that the timing of the hormone replacement therapy that was tested in the WHI, the Women's Health Initiative study, was wrong. timing of treatment is really critical. This is not just for hormones, for any kind of treatment.
5:36You cannot wait years when disease has truly evolved, where the physiological state is different, and then test the impact of your intervention. It's like having a treatment for Alzheimer's disease for the early, you know, most, maybe even preclinical stage of disease, but waiting until full-blown dementia to test it. This is no different. Hormone replacement. Yeah. Well, so Dr. Lahi, when should women start talking to their primary care physicians about hormone replacement therapy? Right around menopause. It's really, really important. And this is really a point that I hope people hear and start doing.
6:20When people are thinking that there may be perimenopausal, that's when the conversation starts, or even before, as you're preparing. to approach the age at which you may go through menopause or early post menopause. We don't actually know how many years can go by before you start hormone replacement therapy. We definitely know a decade is too much. And I would say as early as possible is probably the smartest move. Wait, so let me go back to, because I do think it's safe to say, you know, as a woman, Like there has been that fear when it comes to hormone replacement therapy. So the concerns about cancer, heart disease, that's just not a reality.
7:05There is one kind of cancer that can the risk for which can increase that's uterine cancer. If people are taking only estrogen, this is an important point. If women are considering to take only estrogen, they need to be aware that they need to get very close monitoring. if they still have their uterus. But most hormone replacement therapy are of combination pills. The risk of heart disease, that was just because these were older women and the formulation that was used, the route would also matter. Oral estrogen therapy can increase the risk of coagulation and perhaps other things. So route of administration matters.
7:51Timing of administration really matters. And I would say that we are actually still in the dark with regards to the duration of the administration. That's a really important question remaining to be answered. So what should most women be asking themselves right now in regards to hormone replacement therapy? They need to be having the conversations with their providers and think about each. The providers would need to be thinking about each woman on an individual level. There are pros and cons to every treatment. And hormone replacement therapy in general, no longer are considered risky. And in fact, we think could be really beneficial in the right clinical setting.
8:39If someone has a really high risk for various kinds of cancers, that would need to be taken into account. And the kind of hormone replacement therapy that is being administered would need to be investigated very closely. Women in general are at higher risk for various kinds of cancers, so the routine screening and care does not change. The fact that getting hormone replacement therapy after menopause increases independent of any other risk factors, your risk for breast cancer is no longer true. Interesting. I know we're not supposed to do this, but will you be my doctor? No, it's just... I will be delighted.
9:20Okay. But I'm a brain specialist. I will take care of your brain. Okay. We only have about 30 seconds left, but I do want to know why you think hormone replacement therapy is having a moment right now after so many years of it being questioned by medical professionals.
9:37I'm really delighted because I think we live in an era of precision medicine, And this is one of the many changes that I hope to see implemented in healthcare, where we design the studies really well. But I hope that in the future, we don't make conclusions on group levels anymore either, and that we have biomarker strategies. This is what my lab is really focused on, to make treatment precise for that given individuals to decrease their risk and to maximize their benefit. Will you be all of our doctors? so appreciate it already looking forward to next time Dr. Fannie Allahi she is Associate Professor of Neurology and Neuroscience at the Icahn School of Medicine at Mount Sinai joining us right here in New York City you got to make sure she accepts your insurance I know you didn't check this might be one you pay out of pocket for I'm just saying all right this is never bet against American grit or American energy Through innovation, Venture Global is not only building some of the largest energy facilities in the world right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time.
10:51So while others are busy talking, we're busy building. That's Venture Global. That's unstoppable energy.
11:02Whatever your goal, trade show giveaways, client gifts, or team gear, 4imprint has the promo products to match. With thousands of options, from apparel and drinkware to tech and totes, it's easy to find the right fit for your brand and budget, with standout choices at every price point. And with their 360-degree guarantee, you can be 4imprint certain your order will show up just right, right on time. Explore more at 4imprint.com. For imprint. For certain. When you're running a business, the best days are the ones where priorities stay on track. For midsize and large companies, risk can affect multiple parts of the organization at once, from property and liability to cyber and regulatory challenges.
11:42At that level, managing risk becomes an ongoing discipline. At the Hartford, the focus is on helping businesses manage risk before it turns into something more disruptive. And when losses do happen, that work is paired with insurance coverage shaped by years of underwriting, risk engineering, and claims experience. Learn more at thehartford.com slash risk mitigation. Policies provided by Hartford Fire Insurance Company and its property and casualty affiliates, Hartford, Connecticut. From game day crowds to memorable meals, Genius by Global Payments keeps your kitchen and floor perfectly in sync.
12:17Real-time menus, seamless updates, big league reliability for any business. That's genius.
From the publisher
Hormone replacement therapies (HRTs) used to treat menopause symptoms no longer need to carry strict warnings about some potential side effects, including cancer and heart disease, the US Food and Drug Administration announced Monday. Commissioner Marty Makary said the agency is asking drugmakers to remove the strict black box warnings, with the goal of encouraging more women to take them. Labels on the medicines currently list potential side effects including cardiovascular disease, blood clots, breast cancer and dementia.
Fanny Elahi, MD, PhD is a physician-scientist and Associate Professor in the Departments of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. Dr. Elahi discusses the implications of this move and the importance of such therapies, particularly for women approaching menopause, with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.
See omnystudio.com/listener for privacy information.
